Monoclonal antibody therapy of B cell lymphoma

Bibliography

• EHRLICH P: Collected Studies on Immunity Ehrlich P (Ed.), J. Wiley & sons, New York (1906).
   Google Scholar
• KOHLER G, MILSTEIN C: Continuous cultures of fused cells secreting antibody of predefined specificity. Nature (1975) 256:495.
   PubMed Web of Science ®Google Scholar
• ••The landmark publication describingthe hybridoma technique and production of mAbs.
   Google Scholar
• NADLER LM, STASHENKO P, HARDY R et al.: Serotherapy of a patient with a monoclonal antibody directed against a human lymphoma-associated antigen. Cancer Res. (1980) 40:3147–3154.
   PubMed Web of Science ®Google Scholar
• NADLER LM, RITZ J, GRIFFIN JD et al: Diagnosis and treatment of human leukemias and lymphomas utilizing monoclonal antibodies. Prog. Hematol (1981) 12:187–225.
   PubMedGoogle Scholar
• MEEKER TC, LOWDER J, MALONEY DG et al.: A clinical trial of anti-idiotype therapy for B cell malignancy. Blood(1985) 65:1349–1363.
   PubMed Web of Science ®Google Scholar
• ••The first demonstration that mAb therapyof lymphoma could be safe and effective.
   Google Scholar
• MEEKER T, LOWDER J, CLEARY ML et al.: Emergence of idiotype variants during treatment of B-cell lymphoma with anti-idiotype antibodies. N Engl. J. Med. (1985) 312:1658–1665.
   PubMed Web of Science ®Google Scholar
• FISHWILD DM, O& DONNELL SL, BENGOECHEA T et al.: High-avidity human IgG kappa monoclonal antibodies from a novel strain of minilocus transgenic mice. Nat. Biotechnol (1996) 14:845–851.
   Google Scholar
• MALONEY DG, GRILLOLOPEZ AJ, WHITE CA et al: IDEC-C2B8 (rituximab) anti-CD20 monoclonal antibody therapy patients with relapsed low-grade non-Hodgkins lymphoma. Blood (1997) 90:2188–2195.
   PubMed Web of Science ®Google Scholar
• MALONEY DG, GRILLO-LOPEZ AJ, BODKIN DJ et al.: IDEC-C2B8: results of a Phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma [see comments]. J. Clin. Oncol (1997) 15:3266–3274.
   PubMed Web of Science ®Google Scholar
• •The description of rituximab administered using the standard four times weekly regimen.
   Google Scholar
• MCLAUGHLIN P, GRILLO-LOPEZ AJ, LINK BK et al.: Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. Clin. Oncol (1998) 16:2825-2833. A description of the Phase II trial of rituximab that led to its FDA approval and widespread use.
   Google Scholar
• HOFMEISTER JK, COONEY D, COGGESHALL KM: Clustered CD20 induced apoptosis: src-family kinase, the proximal regulator of tyrosine phosphorylation, calcium influx, and caspase 3-dependent apoptosis. Blood Cells MM. Dis. (2000) 26:133–143.
   PubMed Web of Science ®Google Scholar
• SHAN D, LEDBETTER JA, PRESS OW: Signaling events involved in anti-CD20-induced apoptosis of malignant human B cells. Cancer Immunol Immunother. (2000) 48:673–683.
   PubMed Web of Science ®Google Scholar
• CRAGG MS, MORGAN SM, CHAN HT et al: Complement-mediated lysis by anti-CD20 mAb correlates with segregation into lipid rafts. Blood(2003) 101:1045–1052.
   PubMed Web of Science ®Google Scholar
• DEANS JP, LI H, POLYAK MJ: CD 20-mediatedapoptosis: signalling through lipid rafts. Immunology (2002) 107:176–182.
   PubMed Web of Science ®Google Scholar
• BAINS SK, MONE A, YUN TSO J et al: Mitochondria control of cell death induced by anti-HLA-DR antibodies. Leukemia (2003) 17:1357–1365.
   PubMed Web of Science ®Google Scholar
• VAN OJIK HH, BEVAART L, DAHLE CE et al: CpG-A and B oligodeoxynucleotides enhance the efficacy of antibody therapy by activating different effector cell populations. Cancer Res. (2003) 63:5595–5600.
   PubMed Web of Science ®Google Scholar
• CLYNES RA, TOWERS TL, PRESTA LG, RAVETCH IV: Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nat. Med. (2000) 6:443–446.
   PubMed Web of Science ®Google Scholar
• ••Studies using transgenic mice demonstrating Fc receptors play a central role in the antitumour response to mAb.
   Google Scholar
• CARTRON G, DACHEUX L, SALLES G et al.: Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood (2002) 99:754–758.
   PubMed Web of Science ®Google Scholar
• ••Landmark study correlating expression of ahigh-affinity CD 16 receptor polymorphism with clinical response to rituximab.
   Google Scholar
• GOLAY J, ZAFFARONI L, VACCARI T et al.: Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis. Blood (2000) 95:3900–3908.
   PubMed Web of Science ®Google Scholar
• HARJUNPAA A, JUNNIKKALA S, MERI S: Rituximab (anti-CD20) therapy of B-cell lymphomas: direct complement killing is superior to cellular effector mechanisms. Scand. j Immunol (2000) 51:634–641.
   PubMed Web of Science ®Google Scholar
• WENG WK, LEVY R: Expression of complement inhibitors CD46, CD55, and CD59 on tumor cells does not predict clinical outcome after rituximab treatment in follicular non-Hodgkin lymphoma. Blood (2001) 98:1352–1357.
   PubMed Web of Science ®Google Scholar
• DI GAETANO N, CITTERA E, NOTA R et al.: Complement activation determines the therapeutic activity of rituximab in vivo. Immunol (2003) 171:1581–1587.
   Web of Science ®Google Scholar
• PIRO LD, WHITE CA, GRILLO-LOPEZ AJ et al.: Extended rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma. Ann. Omni (1999) 10:655–661.
   Google Scholar
• HAINS WORTH JD: First-line and maintenance treatment with rituximab for patients with indolent non-Hodgkin's lymphoma. Semin. Oncol (2003) 30:9–15.
   Web of Science ®Google Scholar
• ••Phase II trial suggesting that maintenance rituximab prolongs initial relapse to rituximab.
   Google Scholar
• COLOMBAT P, SALLES G, BROUSSE N et al.: Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation. Blood (2001) 97:101–106.
   PubMed Web of Science ®Google Scholar
• HAINSWORTH JD: Rituximab as first-line and maintenance therapy for patients with indolent non-Hodgkin's lymphoma: interim follow-up of a multicenter Phase II trial. Semin. Omni (2002) 29:25–29.
   Google Scholar
• WILSON WH: Chemotherapy sensitization by rituximab: experimental and clinical evidence. Semin. Oncol. (2000) 27:30–36.
   PubMed Web of Science ®Google Scholar
• •Review of how apoptosis pathways mediated by rituximab and chemotherapy could explain synergy between chemotherapy and rituximab.
   Google Scholar
• CZUCZMAN MS, GRILLO-LOPEZ AJ, WHITE CA et al.: Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. Clin. Oncol. (1999) 17:268–276.
   Web of Science ®Google Scholar
• ••Phase I/II study demonstrating concurrentadministration of rituximab and CHOP is safe and results in durable remissions.
   Google Scholar
• IMRIE KR, LINCH DC, CZUCZMAN MS: Debate on the conservative and aggressive treatment options for the optimal management of indolent non-Hodgkin's lymphoma. Anticancer Drugs (2002) 13\(Suppl. 2):519–524.
   Google Scholar
• VOSE JM, LINK BK, GROSSBARD ML et al.: Phase II study of rituximab in combination with chop chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma. Clin. Oncol. (2001) 19:389–397.
   Web of Science ®Google Scholar
• •Phase II study demonstrating addition of rituximab in patients treated with curative intent does not interfere with CHOP dose-intensity and results in a promising rate of relapse-free survival.
   Google Scholar
• COIFFIER B, LEPAGE E, BRIERE J et al: CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl. I Med. (2002) 346:235–242.
   PubMed Web of Science ®Google Scholar
• ••A randomised Phase III studydemonstrating that concurrent use of rituximab and CHOP in elderly patients improves response, relapse-free survival and overall survival.
   Google Scholar
• HABERMANN TM, WELLER EA, MORRISON VA et al: Phase III trial of rituximab-CHOP (R-CHOP) versus CHOP with a second randomization to maintenance rituximab or observation in patients 60 years of age and older with diffuse large B-cell lymphoma. Blood(2003) 102(11):6a.
   Web of Science ®Google Scholar
• DI GAETANO N, XIAO Y, ERBA E et al:Synergism between fludarabine and rituximab revealed in a follicular lymphoma cell line resistant to the cytotoxic activity of either drug alone. Br. Haematol. (2001) 114:800–809.
   PubMed Web of Science ®Google Scholar
• MCLAUGHLIN P, HAGEMEISTER FB, RODRIGUEZ MA et al: Safety of fludarabine, mitoxantrone, and dexamethasone combined with rituximab in the treatment of stage IV indolent lymphoma. Semin. Omni (2000) 27:37–41.
   Google Scholar
• •Describes safety of therapy with the combination of fludarabine and rituximab.
   Google Scholar
• CZUCZMAN MS, FALLON A, MOHR Aet al.: Rituximah in combination with CHOP or fludarabine in low-grade lymphoma. Semin. Omni (2002) 29:36–40.
   Google Scholar
• MAGNI M, DI NICOLA M, DEVIZZI L et al.: Successful in vivo purging of CD34-containing peripheral blood harvests in mantle cell and indolent lymphoma: evidence for a role of both chemotherapy and rituximab infusion. Blood (2000) 96:864–869.
   PubMed Web of Science ®Google Scholar
• BASHAM TY, KAMINSKI MS, KITAMURA K, LEVY R, MERIGAN TC: Synergistic antitumor effect of interferon and anti-idiotype monoclonal antibody in murine lymphoma. I Immunol. (1987) 137:3019–3024.
   Web of Science ®Google Scholar
• BERINSTEIN N, STARNES CO, LEVY R: Specific enhancement of the therapeutic effect of anti-idiotype antibodies on a murine B cell lymphoma by IL-2.j Immunol. (1988) 140:2839–2845.
   PubMed Web of Science ®Google Scholar
• OZAKI S, KOSAKA M, WAKAHARA Y et al.: Humanized anti-HM1.24 antibody mediates myeloma cell cytotoxicity that is enhanced by cytokine stimulation of effector cells. Blood (1999) 93:3922–3930.
   Google Scholar
• WOOLDRIDGE JE, BALLAS Z, KRIEG AM, WEINER GJ: Immunostimulatory oligodeoxynucleotides containing CpG motifs enhance the efficacy of monoclonal antibody therapy of lymphoma. Blood (1997) 89:2994–2998.
   PubMed Web of Science ®Google Scholar
• •Murine model suggesting irnmunostirnulatory agents that enhance ADCC can enhance efficacy of mAb therapy.
   Google Scholar
• BROWN SL, MILLER RA, HORNING SJ et al.: Treatment of B-cell lymphomas with anti-idiotype antibodies alone and in combination with alpha interferon. Blood (1989) 73:651–661.
   PubMed Web of Science ®Google Scholar
• DAVIS TA, MALONEY DG, CZERWINSKI DK, LILES TM, LEVY R: Anti-idiotype antibodies can induce long-term complete remissions in non-Hodgkin's lymphoma without eradicating the malignant clone. Blood (1998) 92:1184–1190.
   PubMed Web of Science ®Google Scholar
• SACCHI S, FEDERICO M, VITOLO U et al.: Clinical activity and safety of combination immunotherapy with IFN-alpha 2a and rituximab in patients with relapsed low grade non-Hodgkin's lymphoma. Haematologica (2001) 86:951–958.
   PubMed Web of Science ®Google Scholar
• KIMBY E: Beyond immunochemotherapy: combinations of rituximab with cytokines interferon-alpha2a and granulocyte colony stimulating factor [corrected]. Semin. Oncol. (2002) 29:7–10.
   PubMed Web of Science ®Google Scholar
• FRIEDBERG JW, NEUBERG D, GRIBBEN JG et al.: Combination immunotherapy with rituximab and interleukin 2 in patients with relapsed or refractory follicular non-Hodgkin's lymphoma. Br. Haematol. (2002) 117:828–834.
   PubMed Web of Science ®Google Scholar
• ANSELL SM, WITZIG TE, KURTIN PJ et al.: Phase I study of interleukin-12 in combination with rituximab in patients with B-cell non-Hodgkin lymphoma. Blood (2002) 99:67–74.
   PubMed Web of Science ®Google Scholar
• JAHRSDORFER B, WEINER GJ: Immunostimulatory CpG oligodeoxynucleotides and antibody therapy of cancer. Semin. Oncol. (2003) 30:476–482.
   PubMed Web of Science ®Google Scholar
• JAHRSDORFER B, HARTMANN G, RACILA E et al.: CpG DNA increases primary malignant B cell expression of costimulatory molecules and target antigens. Leukoc. Biol. (2001) 69:81–88.
   PubMed Web of Science ®Google Scholar
• LEUNG SO, GOLDENBERG DM, DION AS et al.: Construction and characterization of a humanized, internalizing, B-cell (CD22)-specific, leukemia/lymphoma antibody, LL2. MM. Immunol. (1995) 32:1413–1427.
   PubMed Web of Science ®Google Scholar
• LEONARD JP, COLEMAN M, KETAS JC et al.: Phase I/II trial of epratuzumab (humanized anti-CD22 antibody) in indolent non-Hodgkin's lymphoma. I Clin. Oncol. (2003) 21:3051–3059.
   PubMed Web of Science ®Google Scholar
• LEONARD JP: Immunotherapy of NHL with epratuzumab (anti-CD22 monoclonal antibody): excellent tolerability with objective responses. (2000) Proc. Am. Soc. Clin. Oncol. 19:17a.
   Google Scholar
• LEONARD JP: Epratuzumab (anti-CD22) and rituximab (anti-CD20) combination immunotherapy for non-Hodgkin's lymphoma: preliminary response data. Proc. Am. Soc. Gin. Oncol (2002) 21:266a.
   Google Scholar
• MICALLEF IN, KAHL BS, GAYKO U et al.: A pilot study of epratuzumab and rituximab in combination with CHOP chemotherapy in previously untreated patients with diffuse large B-cell lymphoma. Blood(2003) 102(11):643a.
   Web of Science ®Google Scholar
• GINGRICH RD, DAHLE CE, HOSKINS KF, SENNEFF MJ: Identification and characterization of a new surface membrane antigen found predominantly on malignant B lymphocytes. Blood (1990) 75:2375–2387.
   PubMed Web of Science ®Google Scholar
• KOSTELNY SA, LINK BK, TSO JY et al: Humanization and characterization of the anti-HLA-DR antibody 1D10. Int. Cancer (2001) 93:556–565.
   PubMed Web of Science ®Google Scholar
• LINK BK, WANG H, BYRD JC et al: Phase I study of Hul D10 monoclonal antibody in patients with B-cell lymphoma. Proc. Am. Soc. Gin. Oncol (2001) 20:284a.
   Google Scholar
• LINK BK: Prolonged clinical responses in patients with follicular lymphoma treated on a Phase I trial of the anti-HLA-DR monoclonal antibody RemitogenTm (Hu1D10). Proc. Am. Soc. Hematol (2001) 98:244b.
   Google Scholar
• SALISBURY JR, RAPSON NT, CODD JD, ROGERS MV, NETHERSELL AB: Immunohistochemical analysis of CDw52 antigen expression in non-Hodgkin's lymphomas. I Clin. Pathol (1994) 47:313–317.
   PubMed Web of Science ®Google Scholar
• OSTERBORG A, DYER MJ, BUNJES D et al.: Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. European Study Group of CAMPATH-1H Treatment in Chronic Lymphocytic Leak. Clin. Omni (1997) 15:1567–1574.
   Google Scholar
• KHORANA A, BUNN P, MCLAUGHLIN P et al: A Phase II multicenter study of CAMPATH-1H antibody in previously treated patients with nonbulky non-Hodgkin's lymphoma. Leak. Lymphoma (2001) 41:77–87.
   PubMed Web of Science ®Google Scholar
• LUNDIN J, OSTERBORG A, BRITTINGER Get al.: CAMPATH-1H monoclonal antibody in therapy for previously treated low-grade non-Hodgkin's lymphomas: a Phase II multicenter study. European Study Group of CAMPATH-1H Treatment in Low-Grade Non-Hodgkin's Lymphoma. I Clin. Omni (1998) 16:3257–3263.
   Google Scholar
• ENBLAD G, HAGBERG H, ERIKSSON M et al.: A pilot study of alemtuzumab (anti-CD52 monoclonal antibody) therapy for patients with relapsed or chemotherapy-refractory peripheral T-cell lymphoma. Blood (2003) 102(11):643a.
   Google Scholar
• YOUNES A, HARIHARAN K, ALLEN RS, LEIGH BR: Initial trials of anti-CD80 monoclonal antibody (galiximab) therapy for patients with relapsed or refractory follicular lymphoma. Gin. Lymphoma (2003) 3:257–259.
   PubMed Web of Science ®Google Scholar
• •Preliminary report on the activity of anti-CD80 mAb.
   Google Scholar
• ORDER SE: The history and progress of serologic immunotherapy and radiodiagnosis. Radiology (1976) 118:219–223.
   PubMed Web of Science ®Google Scholar
• ILLIDGE TM, JOHNSON PW: The emerging role of radioimmunotherapy in haematological malignancies. Br. Haematol (2000) 108:679–688.
   PubMed Web of Science ®Google Scholar
• DILLMAN RO: Radiolabeled anti-CD 20 monoclonal antibodies for the treatment of B-cell lymphoma. Clin. Oncol (2002) 20:3545–3557.
   Web of Science ®Google Scholar
• ••A useful and comprehensive review of theclinical experience so far with radiolabelled antilymphoma mAbs.
   Google Scholar
• KAMINSKI MS, ZASADNY KR, FRANCIS IR et al: Iodine-131 - anti-Bl radioimmunotherapy for B-cell lymphoma. Gin. Oncol (1996) 14:1974–1981.
   Web of Science ®Google Scholar
• •Demonstration of the antiturnour effect of radiolabelled mAb administered at non-myeloablative doses.
   Google Scholar
• LIU SY, EARY JF, PETERSDORF SH et al.: Follow-up of relapsed B-cell lymphoma patients treated with iodine-131-labeled anti-CD20 antibody and autologous stem-cell rescue. J. Clin. Oncol (1998) 16:3270–3278.
   PubMed Web of Science ®Google Scholar
• WITZIG TE, WHITE CA, WISEMAN GA et al.: Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20(+) B-cell non-Hodgkin's lymphoma. I Gin. Oncol (1999) 17:3793–3803.
   Web of Science ®Google Scholar
• WITZIG TE, WHITE CA, GORDON LI et al.: Safety of yttrium-90 ibritumomab tiiixetan radioimmunotherapy for relapsed low-grade, follicular, or transformed non-Hodgkin's lymphoma. I Gin. Oncol (2003) 21:1263–1270.
   Web of Science ®Google Scholar
• WITZIG TE, GORDON LI, CABANILLAS F et al.: Randomized controlled trial of yttrium-90-labeled ibritumomab tiiixetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. I Clin. Oncol (2002) 20:2453–2463.
   PubMed Web of Science ®Google Scholar
• ••A Phase III study comparing the clinicalefficacy and toxicity of rituximab versus ibritumomab tiuxetan.
   Google Scholar
• PRESS OW, UNGER JM, BRAZIEL RM et at A Phase II trial of CHOP chemotherapy followed by tositumomab/ iodine 1131 tositumomab for previously untreated follicular non-Hodgkin lymphoma: Southwest Oncology Group Protocol S9911. Blood (2003) 102: 1606-1612.
   Google Scholar
• ••The first large study combining sequentialCHOP followed by radioirmnunotherapy.
   Google Scholar
• VOSE JM, COLCHER D, GOBAR L et al.: Phase I/II trial of multiple dose 131Iodine-MAb LL2 (CD22) in patients with recurrent non-Hodgkin's lymphoma. Leak. Lymphoma (2000) 38:91–101.
   PubMed Web of Science ®Google Scholar
• DENARDO GL, LAMBORN KR, GOLDSTEIN DS, KROGER LA, DENARDO SJ: Increased survival associated with radiolabeled Lym-1 therapy for non-Hodgkins lymphoma and chronic lymphocytic leukemia. Cancer (1997) 80:2706–2711.
   PubMed Web of Science ®Google Scholar
• GROSSBARD ML, LAMBERT JM, GOLDMACHER versus et al.: Anti-B4-blocked ricin - a Phase-I trial of 7-day continuous infusion in patients with B-cell neoplasms. Clin. Oncol (1993) 11:726–737.
   Web of Science ®Google Scholar
• GROSSBARD ML, FREEDMAN AS, RITZ J et al.: Serotherapy of B-cell neoplasms with anti-B4-blocked ricin - a Phase-I trial of daily bolus infusion. Blood (1992) 79:576–585.
   PubMed Web of Science ®Google Scholar
• VITETTA ES, STONE M, AMLOT P et al.: Phase-I immunotwdn trial in patients with B-cell lymphoma. Cancer Res. (1991) 51:4052–4058.
   PubMed Web of Science ®Google Scholar
• AMLOT PL, STONE MJ, CUNNINGHAM D et al.: A Phase-I study of an anti-CD22-deglycosylated ricin-A chain immunotwdn in the treatment of B-cell lymphomas resistant to conventional therapy. Blood (1993) 82:2624–2633.
   PubMed Web of Science ®Google Scholar